Personalized Thromboprophylaxis for Peripheral Artery Disease

This trial investigates whether a personalized approach to preventing blood clots is more effective than the standard method for individuals with peripheral artery disease (PAD) who have undergone surgery to improve leg blood flow. It evaluates whether the personalized plan can better reduce blood clots, amputations, repeat surgeries, bleeding, and death compared to usual treatments. Participants will join either a personalized treatment group, where medication is adjusted based on blood tests, or a standard treatment group. Individuals who have had a procedure to restore blood flow in their legs due to PAD and are experiencing PAD-related issues might be suitable candidates for this trial. As an unphased trial, this study provides a unique opportunity to explore innovative treatments that could enhance health outcomes.

The trial information does not specify if you need to stop your current medications. However, since the trial involves adjusting medications based on blood test results, it's possible that changes to your medication regimen might be required.

Previous studies have used a test called thromboelastography with platelet mapping (TEG-PM) to tailor treatment for people with peripheral artery disease (PAD). This test helps doctors assess blood clotting to adjust medications and lower the risk of blood clots. Research has shown that TEG-PM can predict clotting risks and guide the safer use of blood-thinning treatments.

The trial involves medications like aspirin, clopidogrel, rivaroxaban, and ticagrelor, which are common blood thinners. These medications are usually well-tolerated, but they can have side effects. The most common side effect is bleeding, although serious bleeding is rare.

Researchers are excited about this trial because it's exploring a personalized approach to preventing blood clots in people with Peripheral Artery Disease (PAD). Unlike the standard treatment, which typically follows a one-size-fits-all protocol, this approach uses Thromboelastography with Platelet Mapping (TEG-PM) to guide therapy. By adjusting medication based on real-time platelet activity, the goal is to keep blood clot prevention within a safe range, potentially improving outcomes and reducing side effects. This tailored strategy could lead to more effective and safer management of PAD compared to current methods.

Research has shown that thromboelastography with platelet mapping (TEG-PM) can help customize treatment for patients with peripheral artery disease (PAD) and predict their health outcomes. In this trial, participants in the TARGET arm will have their antiplatelet therapy adjusted based on TEG-PM results to maintain platelet inhibition within a therapeutic window. Even with standard treatment, up to 17% of patients develop blood clots within six months after procedures to improve blood flow. TEG-PM provides a detailed, personalized view of blood clot formation, enabling doctors to adjust treatments. Studies have found that 60-65% of patients do not fully respond to standard antiplatelet therapy, suggesting that a personalized approach could lead to better results. This method aims to prevent excessive platelet clumping, reducing the risk of clots, repeat procedures, and other complications.¹²³⁴⁶